Prostate Cancer

The presence of certain comorbidities prior to androgen deprivation therapy (ADT) for prostate cancer may be associated with a greater risk of cardiovascular events after starting ADT, recent research found.

A cross-sectional survey of patient preferences found that the out-of-pocket cost of treatment was the most impactful attribute for patients when choosing an androgen deprivation therapy (ADTs) for their prostate cancer.

The use of active surveillance for indolent prostate cancer cases continues to rise in the United States, but rates of use are lower in minority groups, low-income groups, and patients in rural areas, a recent study found.

Reducing health care disparities may require shifting from providing equal care to providing equitable care.

Treatment with relugolix and concomitant therapies for prostate cancer showed similar safety and efficacy to relugolix alone in a recent study.

Patients with prostate cancer who were treated with brachytherapy boost showed improved survival compared with those treated with external beam radiotherapy in a recent study.

Extended follow-up data from the ProtecT trial highlight the importance of weighing the risks associated with radical treatment versus active surveillance for newly diagnosed localized prostate cancer.

The findings, published in the Journal of the National Comprehensive Cancer Network, add to the evidence that the shift to precision medicine is built on data that have not included sufficient numbers of patients of color.

The new report found polygenic risk scores likely will not help identify patients at highest risk.

Rates of active surveillance for low-risk prostate cancer have improved nationally but vary locally and remain subpar overall, according to findings from a study published in JAMA Network Open.

Overall survival, cancer-specific survival and progression-free survival were all negatively affected by elevated C-reactive protein levels, this study found.

Relugolix was frequently used in combination with other medications for prostate cancer in patients both new to androgen-deprivation therapy and continuing androgen-deprivation therapy in a real-world study.

The study found 143 loci where somatic copy numbers were varied based on genetic ancestry.

A randomized controlled trial found that the use of a rectal spacer may help mitigate the gastrointestinal (GI) toxicity associated with hypofractionated radiation therapy for prostate cancer.

The method had high rates of sensitivity and specificity, although its sensitivity was somewhat lower in cases of localized prostate cancer.

A novel test developed at Cedars-Sinai Medical Center was able to detect and characterize even microscopic amounts of prostate cancers and could potentially help individualize treatment in the clinical setting.

Health care expert and lived experience panels came to a consensus on several aspects that should be considered in the decision to offer and continue active surveillance for prostate cancer.

The report also suggests that ataxia telangiectasia and Rad3-related protein inhibition could be a valuable tool to overcome resistance.

The report suggests that high-resolution micro-ultrasound could help identify clinically significant lesions that would be missed with conventional MRI.

The importance of identifying rare pathogenic mutations and genetic risk score among patients was explored in this new analysis, with goals that included reducing mortality and early disease detection.

A meta-analysis supported that Black men have similar or better prostate cancer outcomes compared with White men when health care access is equal and treatment is standardized for all patients.

Following the release of its 2023 report on cancer statistics, the American Cancer Society announced a new initiative to improve prostate cancer outcomes and reduce disparities.

Darolutamide, sold as Nubeqa, is an androgen receptor inhibitor, which works to limit prostate cell growth by preventing the binding of hormones, or androgens, to proteins known as androgen receptors.

Experts consider available professional society guidelines on prostate cancer and cardiovascular disease management.

A brief review of factors that may put patients with prostate cancer at increased risk for developing cardiovascular disease.

Reasons for pursuing genomic profiling among patients with advanced bladder, renal, and prostate cancers included guiding treatment and improving treatment response, in which age and education level were found to significantly influence shared decision-making.

Focusing on available agents in prostate cancer, experts consider how androgen deprivation therapy impacts risk of cardiovascular disease.

A comprehensive review of the therapeutic classes available for patients with prostate cancer.

Shared insight on the correlation between prostate cancer and cardiovascular disease, with a focus on the attributes that increase a patient’s risk.

A broad look at the economic burden of prostate cancer and outlook in regard to survival within the current treatment landscape.